PMID- 22499721
OWN - NLM
STAT- MEDLINE
DCOM- 20130122
LR  - 20191210
IS  - 1553-3840 (Electronic)
IS  - 1553-3840 (Linking)
VI  - 9
DP  - 2012 Jan 12
TI  - Anti-inflammatory effects of shea butter through inhibition of iNOS, COX-2, and 
      cytokines via the Nf-kappaB pathway in LPS-activated J774 macrophage cells.
PG  - Article 4
LID - /j/jcim.2012.9.issue-1/1553-3840.1574/1553-3840.1574.xml [pii]
LID - 10.1515/1553-3840.1574 [doi]
AB  - Shea butter is traditionally used in Africa for its anti-inflammatory and 
      analgesic effects. In this study we explored the anti-inflammatory activities of 
      the methanolic extract of shea butter (SBE) using lipopolysaccharide 
      (LPS)-induced murine macrophage cell line J774. It was observed that SBE 
      significantly reduced the levels of LPS-induced nitric oxide, Tumor necrosis 
      factor-alpha (TNF-alpha), interleukins, 1beta (IL-1beta), and -12 (IL-12) in the culture 
      supernatants in a dose dependent manner. Expression of pro-inflammatory enzymes, 
      inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) were also 
      inhibited by SBE. These anti-inflammatory effects were due to an inhibitory 
      action of SBE on LPS-induced iNOS, COX-2, TNF-alpha, IL-1beta, and IL-12 mRNA 
      expressions. Moreover, SBE efficiently suppressed IkappaB phosphorylation and NF-kappaB 
      nuclear translocation induced by LPS. These findings explain the molecular bases 
      of shea butter's bioactivity against various inflammatory conditions and 
      substantiate it as a latent source of novel therapeutic agents.
FAU - Verma, Nandini
AU  - Verma N
AD  - Institute of Genomics and Integrative Biology.
FAU - Chakrabarti, Rina
AU  - Chakrabarti R
FAU - Das, Rakha H
AU  - Das RH
FAU - Gautam, Hemant K
AU  - Gautam HK
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20120112
PL  - Germany
TA  - J Complement Integr Med
JT  - Journal of complementary & integrative medicine
JID - 101313855
RN  - 0 (Biomarkers)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (NF-kappa B)
RN  - 0 (Plant Extracts)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 187348-17-0 (Interleukin-12)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - EC 1.14.13.39 (Nos2 protein, mouse)
RN  - EC 1.14.99.- (Ptgs2 protein, mouse)
RN  - EC 1.14.99.1 (Cyclooxygenase 2)
SB  - IM
MH  - Animals
MH  - Biomarkers/metabolism
MH  - Blotting, Western
MH  - Cell Line
MH  - Cyclooxygenase 2/metabolism
MH  - Dose-Response Relationship, Drug
MH  - Interleukin-12/metabolism
MH  - Interleukin-1beta/metabolism
MH  - Lipopolysaccharides/pharmacology
MH  - Macrophages/*drug effects/metabolism
MH  - Mice
MH  - NF-kappa B/metabolism
MH  - Nitric Oxide Synthase Type II/metabolism
MH  - Plant Extracts/*pharmacology
MH  - Plants, Medicinal
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - *Sapotaceae
MH  - Seeds
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 2012/04/14 06:00
MHDA- 2013/01/23 06:00
CRDT- 2012/04/14 06:00
PHST- 2012/04/14 06:00 [entrez]
PHST- 2012/04/14 06:00 [pubmed]
PHST- 2013/01/23 06:00 [medline]
AID - /j/jcim.2012.9.issue-1/1553-3840.1574/1553-3840.1574.xml [pii]
AID - 10.1515/1553-3840.1574 [doi]
PST - epublish
SO  - J Complement Integr Med. 2012 Jan 12;9:Article 4. doi: 10.1515/1553-3840.1574.